A 52-week Double-blind, Randomized, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of SAR425899 for the Treatment of Non-alcoholic Steatohepatitis (NASH)

Trial Profile

A 52-week Double-blind, Randomized, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of SAR425899 for the Treatment of Non-alcoholic Steatohepatitis (NASH)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs SAR 425899 (Primary)
  • Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms Restore
  • Sponsors Sanofi
  • Most Recent Events

    • 11 Apr 2018 Planned End Date changed from 1 Jul 2020 to 26 May 2021.
    • 11 Apr 2018 Planned primary completion date changed from 1 Jul 2020 to 26 May 2021.
    • 11 Apr 2018 Planned initiation date changed from 30 Apr 2018 to 21 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top